Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients

Sammy Al-Benna, Sammy Al-Benna

Abstract

Introduction: Obese patients have an increased risk of COVID-19 critical illness leading to ICU admission or death compared to normal weight individuals. SARS-CoV-2 binding to angiotensin-converting enzyme 2 (ACE2) receptor is a critical step mediate virus entry into target cells. Articles have alluded that the level of ACE2 gene expression in adipose tissue is higher than lung tissue, but a PubMed search found no results in articles to demonstrate this. The aim of this study was to investigate ACE2 gene expression in adipose tissue and lung tissue using a public database.

Material and methods: A search of a public gene expression database to investigate ACE2 gene expression in human tissues.

Results: ACE2 gene expression was present in both visceral and subcutaneous adipose tissues. The gene expression profile demonstrated that ACE2 gene expression was higher in human visceral and subcutaneous adipose tissues than human lung tissue.

Conclusion: This study demonstrates that ACE2 gene expression is higher in visceral and subcutaneous adipose tissue than that in lung tissue, a major target tissue affected by SARS-CoV-2 infection. This suggests a mechanism by which excess adiposity may drive greater infection severity in patients with COVID-19.

Keywords: ACE, angiotensin converting enzyme; ACE2, angiotensin converting enzyme-2; AT(1–7), angiotensin (1–7); AT1, angiotensin 1; AT2, angiotensin 2; Adipose tissue; Angiotensin converting enzyme 2 receptor; COVID-19; COVID-19, Coronavirus disease 2019; Coronavirus; SARS CoV, severe acute respiratory syndrome coronavirus; SARS CoV-2, severe acute respiratory syndrome coronavirus-2; Severe acute respiratory syndrome coronavirus 2.

Conflict of interest statement

None.

© 2020 Elsevier Ltd. All rights reserved.

Figures

Fig. 1
Fig. 1
ACE2 gene expression in human subcutaneous adipose tissue, human visceral adipose tissue and human lung tissue.

References

    1. Abbas A.M., Fathy S.K., Fawzy A.T., Salem A.S., Shawky M.S. The mutual effects of COVID-19 and obesity. Obes Med. 2020;19 doi: 10.1016/j.obmed.2020.100250.
    1. Abbas A.M., Kamel M.M. Dietary habits in adults during quarantine in the context of COVID-19 pandemic [published online ahead of print, 2020 May 15] Obes Med. 2020;19 doi: 10.1016/j.obmed.2020.100254.
    1. Al-Benna S. Availability of COVID-19 information from national and international aesthetic surgery society websites. Aesthetic Plast. Surg. 2020;44:1043–1046. doi: 10.1007/s00266-020-01751-w.
    1. Al-Benna S. Management of hand surgery services during the Coronavirus Disease 2019 pandemic. J. Hand Microsurg. 2020 doi: 10.1055/s-0040-1714440.
    1. Al-Benna S. Concepts of management of plastic surgery services during the Coronavirus Disease 2019 pandemic. Eur. J. Plast. Surg. 2020 doi: 10.1007/s00238-020-01704-1.
    1. Al-Benna S., Gohritz A. Availability of COVID-19 information from national plastic surgery society websites. Ann. Plast. Surg. 2020 doi: 10.1097/SAP.0000000000002447.
    1. Al-Benna S., Gohritz A. Availability of COVID-19 information from national and international burn society websites. Ann Burns Fire Disasters. 2020 In press.
    1. Al-Benna S., Hamilton C.A., McClure J.D., Rogers P.N., Berg G.A., Ford I., Delles C., Dominiczak A.F. Low-density lipoprotein cholesterol determines oxidative stress and endothelial dysfunction in saphenous veins from patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2006;26:218–223.
    1. Belančić A., Kresović A., Rački V. Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity. Obes. Med. 2020;19 doi: 10.1016/j.obmed.2020.100259.
    1. Edler C., Schröder A.S., Aepfelbacher M. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int. J. Leg. Med. 2020;134:1275–1284. doi: 10.1007/s00414-020-02317-w.
    1. Englmeier L. A theory on SARS-COV-2 susceptibility: reduced TLR7-activity as a mechanistic link between men, obese and elderly. J. Biol. Regul. Homeost. Agents. 2020;34:10–23812. doi: 10.23812/20-221-L-49.
    1. Hajifathalian K., Kumar S., Newberry C. Obesity is associated with worse outcomes in COVID- 19: analysis of early data from New York city. Obesity. 2020 doi: 10.1002/oby.22923.
    1. Hamilton C.A., Brosnan M.J., Al-Benna S., Berg G., Dominiczak A.F. NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension. 2002;40:755–762.
    1. Hamilton C.A., Miller W.H., Al-Benna S., Brosnan M.J., Drummond R.D., McBride M.W., Dominiczak A.F. Strategies to reduce oxidative stress in cardiovascular disease. Clin. Sci. (Lond.) 2004;106:219–234. 2004.
    1. Imafidon C.E., Akomolafe R.O. Obesity-induced renal injury is associated with oxidative stress via renal ischemia reperfusion injury. Obes Med. 2019;14
    1. Kim Y.A., Cho Y.J. The association between visceral fat, subcutaneous fat and serum 25-hydroxyvitamin D3 levels. Obes Med. 2019;13:29–33. doi: 10.1016/j.obmed.2018.12.005.
    1. Korakas E., Ikonomidis I., Kousathana F. Obesity and COVID- 19: immune and metabolic derangement as a possible link to adverse clinical outcomes. Am. J. Physiol. Endocrinol. Metab. 2020 doi: 10.1152/ajpendo.00198.2020.
    1. Lifeome 2020 is HCCDB database. 2020.
    1. Mattioli A.V., Pinti M., Farinetti A., Nasi M. Obesity risk during collective quarantine for the COVID-19 epidemic. Obes Med. 2020 doi: 10.1016/j.obmed.2020.100263.
    1. Mediouni M., Madiouni R., Kaczor-Urbanowicz K.E. COVID-19: how the quarantine could lead to the depreobesity. Obes Med. 2020;19 doi: 10.1016/j.obmed.2020.100255.
    1. Meng J., Xiao G., Zhang J. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg. Microb. Infect. 2020;9(1):757–760. doi: 10.1080/22221751.2020.1746200.
    1. Moriconi D., Masi S., Rebelos E. Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding. Obes. Res. Clin. Pract. 2020;403:30401–30404. doi: 10.1016/j.orcp.2020.05.009.
    1. Nijhawan P., Arora S., Behl T. Intricate role of oxidative stress in the progression of obesity. Obes Med. 2019;15
    1. Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. J. Am. Med. Assoc. 2020 doi: 10.1001/jama.2020.4683.
    1. Patel A.B., Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. What is the evidence? J. Am. Med. Assoc. 2020;323:1769–1770. doi: 10.1001/jama.2020.4812. 2020.
    1. Pinheiro T.A., Barcala-Jorge A.S., Andrade J.M.O. Obesity and malnutrition similarly alter the renin-angiotensin system and inflammation in mice and human adipose. J. Nutr. Biochem. 2020;48:74–82. doi: 10.1016/j.jnutbio.2017.06.008.
    1. Radzikowska U., Ding M., Tan G. Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020 doi: 10.1111/all.14429.
    1. Rahmati-Ahmadabad S., Hosseini F. Exercise against SARS-CoV-2 (COVID-19): does workout intensity matter? (A mini review of some indirect evidence related to obesity) Obes Med. 2020;19 doi: 10.1016/j.obmed.2020.100245.
    1. Singh P., Rai S.N. Factors affecting obesity and its treatment. Obes Med. 2019;16
    1. World Health Organization . 2020. Obesity and Overweight.
    1. Worldometer . 2020. COVID-19 Coronavirus Pandemic.
    1. Xu Y., Pan J. The adipokines of brown fat. Obes Med. 2020;19
    1. Zhou P., Yang X.L., Wang X.G. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579 doi: 10.1038/s41586-020-2012-7. 270-27.
    1. Ziegler C.G.K., Allon S.J., Nyquist S.K. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016–1035. doi: 10.1016/j.cell.2020.04.035.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj